FANCB and acute myeloid leukemia: Thirdly, although FAB phenotype, patient status and risk molecular, which may affect prognosis of AML patients, were analyzed in the relation analysis with the outcome of AML patients, no significant difference was observed due to the small sample size, especially for the patients undergoing allo‐HSCT (n = 7), or the M3 patients (n = 1), resulting in potential bias.